1-(4-Tert-butyl-3-methoxyphenyl)-4-methylpiperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(4-Tert-butyl-3-methoxyphenyl)-4-methylpiperazine
• 英文别名: 1-(4-tert-butyl-3-methoxyphenyl)-4-methylpiperazine
• 化学式: C₁₆H₂₆N₂O
• 分子量: 262.39
• InChiKey: MRLGBJXJWDYKCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  15.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use
  申请人：AMGEN INC.

  公开号：US20140249131A1

  公开（公告）日：2014-09-04

  The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.

  这项发明涵盖了化合物、类似物、前药和其药用盐，以及用于预防和治疗癌症的药物组合物、用途和方法。
• PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE
  申请人：DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION

  公开号：US20200239474A1

  公开（公告）日：2020-07-30

  The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.

  本发明涉及一种新型吡咯-嘧啶衍生物化合物，其制备方法和制备以该化合物为有效成分的药物组合物，用于预防或治疗蛋白激酶相关疾病。根据本发明，化学式1所表示的化合物、其光学异构体或其药学上可接受的盐，以及包含其作为有效成分的药物组合物，具有对LRRK2激酶和对NIH-3T3细胞系（一种LRRK2表达细胞系）以及NCC01和448T细胞系（均来源于脑肿瘤患者）的磷酸化具有显著的抑制活性。该化合物已经被证实对除LRRK2外的各种蛋白激酶具有抑制活性，因此可以在蛋白激酶相关疾病的治疗或预防中发挥有效作用。
• COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES
  申请人：BEIJING HANMI PHARMACEUTICAL CO., LTD.

  公开号：US20160229865A1

  公开（公告）日：2016-08-11

  The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).

  本发明涉及一种抑制布鲁顿酪氨酸激酶（BTK）和/或Janus激酶3（JAK3）活性的化合物，该化合物的制药组合物，其制药应用，使用该化合物抑制BTK和/或JAK3活性的方法以及使用该化合物治疗和/或预防哺乳动物（尤其是人类）中BTK和/或JAK3介导的疾病或疾病的方法。该化合物的结构式（I）如下：
• Compound inhibiting activities of BTK and/or JAK3 kinases
  申请人：BEIJING HANMI PHARMACEUTICAL CO., LTD.

  公开号：US10273242B2

  公开（公告）日：2019-04-30

  The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).

  本发明涉及一种抑制布鲁顿酪氨酸激酶（BTK）和/或 Janus 激酶 3（JAK3）活性的化合物、该化合物的药物组合物、其药物应用、使用该化合物抑制 BTK 和/或 JAK3 活性的方法，以及使用该化合物治疗和/或预防哺乳动物（尤其是人类）中由 BTK 和/或 JAK3 介导的疾病或紊乱的方法。该化合物由结构式(I)表示。
• Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof
  申请人：HONGYUN BIOTECH CO., LTD.

  公开号：US11078213B2

  公开（公告）日：2021-08-03

  The present invention relates to thienopyrimidine compound, preparation method thereof, pharmaceutical composition and use thereof, and in particular to a type of compounds having ALK and/or c-Met selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with anaplastic lymphoma kinase in vivo, and in the manufacture of a medicament for preventing or treating a disease associated with angiogenesis or cancer metastasis, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.

  本发明涉及噻吩嘧啶化合物、其制备方法、药物组合物及其用途，特别是涉及一种具有ALK和/或c-Met选择性抑制活性的化合物、其制备方法、包含其的药物组合物、以及这些化合物在制造预防或治疗体内无性淋巴瘤激酶相关疾病的药物中的用途，以及在制造预防或治疗血管生成或癌症转移相关疾病的药物中的用途，特别是在制造预防或治疗肿瘤生长和转移的药物中的用途。